ClinicalTrials.gg

Cholangiocarcinoma clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 825 studies for Cholangiocarcinoma across more than 10 countries. 288 are recruiting or about to start. 451 of them are mainly about Cholangiocarcinoma (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its narrower condition Klatskin Tumor too: 872 studies, 300 open.

ClinicalTrials.gov finds 1,101 studies for Cholangiocarcinoma. How that becomes 824 here

This page counts the studies the registry files under Cholangiocarcinoma, and those it files under no condition that list Cholangiocarcinomathemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 1,101Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −47Filed under a narrower condition, counted on its own pageKlatskin Tumor 45
  3. −42List Cholangiocarcinoma as a condition, but the registry did not file them under itMost often written as “Cholangiocarcinoma of the Extrahepatic Bile Duct” (14), “Cholangiocarcinoma of the Gallbladder” (9), and “Adult Primary Cholangiocellular Carcinoma” (6). The registry filed them under other conditions only, most often Gallbladder Neoplasms (16) and Pancreatic Neoplasms (14).
  4. −188Match it another way32 name it in the title, 19 in a keyword, and 137 by a synonym or other text the search reads.
  5. 824The count on this page44 of them list Cholangiocarcinoma in their own words; the registry filed them under no condition.

Status

Completed
234
Recruiting
211
Terminated
103
Status unknown
95
Not yet recruiting
67
Active, not recruiting
64

Phase

Phase 2
365
Phase 1
174
Phase 3
58
Phase 4
8
Early Phase 1
7

Where

United States
328
China
230
France
74
Korea, Republic of
68
Germany
62
Italy
57

Who develops what

Add Cholangiocarcinoma to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 24 programs from 21 companies, 7 with this as their studies’ main aim; 2 with a live phase 3 study; 5 primary completions in the next 12 months. Compare Rigel Pharmaceuticals, Astellas Pharma and Beijing Biotech here →

Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
pembrolizumabRecent, repeated
Evidence
  • NCT07020221 · Verastem, Inc. · Phase 2 · live · background · “Carboplatin + Pemetrexed + Pembrolizumab” · registered May 2025
  • NCT06282575 · Jazz Pharmaceuticals · Phase 3 · live · background · “Pembrolizumab” · registered Feb 2024
  • NCT05732831 · Tango Therapeutics, Inc. · Phase 2 · live · background · “Pembrolizumab” · registered Jan 2023
  • NCT05429697 · SMT bio Co., Ltd. · Phase 3 · live · background · “Pembrolizumab” · registered Jun 2022
  • NCT05220722 · TriSalus Life Sciences, Inc. · Phase 2 · background · “Pembrolizumab” · registered Jan 2022
Merck & Co., Inc74% of its industry studiesUS: Merck & Co., Inc (FDA 2014)EU: Merck & Co., Inc (EMA 2015)55 studies
CapecitabineRecent, repeated
Evidence
  • NCT07328919 · TransThera Sciences (Nanjing), Inc. · Phase 3 · live · comparator · “Oxaliplatin, fluorouracil, calcium folinate, irinotecan, capecitabine” · registered Dec 2025
  • NCT06622057 · InnoPharmax Inc. · Phase 3 · live · background · “Capecitabine” · registered Sep 2024
  • NCT06109779 · AstraZeneca · Phase 3 · live · background · “Capecitabine” · registered Oct 2023
  • NCT05007106 · Merck & Co., Inc · Phase 2 · background · “Capecitabine” · registered Aug 2021
  • NCT04430738 · Pfizer · Phase 2 · live · background · “capecitabine” · registered Jun 2020
Hoffmann-La Roche33% of its industry studiesEU: off-patent, 4 generics authorized33 studies
GemcitabineRecent, repeated
Evidence
  • NCT07020221 · Verastem, Inc. · Phase 2 · live · background · “Gemcitabine + Nab-paclitaxel” · registered May 2025
  • NCT06282575 · Jazz Pharmaceuticals · Phase 3 · live · background · “Gemcitabine” · registered Feb 2024
  • NCT05007106 · Merck & Co., Inc · Phase 2 · background · “Gemcitabine” · registered Aug 2021
  • NCT04924062 · Merck & Co., Inc · Phase 3 · background · “Gemcitabine” · registered Jun 2021
  • NCT04683939 · BioNTech SE · Phase 2 · background · “Gemcitabine” · registered Dec 2020
Eli Lilly and Company30% of its industry studiesUS: off-patent, 11 generics marketed22 studies
fludarabineRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT07641036 · Beijing Biotech · Phase 2 · live · background · “Fludarabine” · registered Jun 2026
  • NCT05451849 · TCR2 Therapeutics · Phase 2 · background · “Fludarabine” · registered Jun 2022
  • NCT03907852 · TCR2 Therapeutics · Phase 2 · live · background · “fludarabine” · registered Apr 2019
Beijing Biotech18% of its industry studies22 studies
CyclophosphamideRecent, repeated
Evidence
  • NCT07641036 · Beijing Biotech · Phase 2 · live · background · “Cyclophosphamide” · registered Jun 2026
  • NCT05451849 · TCR2 Therapeutics · Phase 2 · background · “Cyclophosphamide” · registered Jun 2022
  • NCT03907852 · TCR2 Therapeutics · Phase 2 · live · background · “cyclophosphamide” · registered Apr 2019
Hoffmann-La Roche13% of its industry studiesUS: off-patent, 12 generics marketed22 studies
Albumin-Bound PaclitaxelRecent, repeated
Evidence
  • NCT07020221 · Verastem, Inc. · Phase 2 · live · background · “Gemcitabine + Nab-paclitaxel” · registered May 2025
  • NCT05253053 · TransThera Sciences (Nanjing), Inc. · Phase 2 · background · “Combination Product: Nab-Paclitaxel” · registered Jan 2022
  • NCT04742959 · TransThera Sciences (Nanjing), Inc. · Phase 2 · background · “Nab-Paclitaxel” · registered Feb 2021
  • NCT04683939 · BioNTech SE · Phase 2 · background · “Nab-paclitaxel” · registered Dec 2020
Bristol-Myers Squibb43% of its industry studiesEU: Bristol-Myers Squibb (EMA 2008)22 studies
NivolumabRecent, repeated
Evidence
  • NCT05220722 · TriSalus Life Sciences, Inc. · Phase 2 · background · “Nivolumab” · registered Jan 2022
  • NCT05223816 · Virogin Biotech Canada Ltd · Phase 2 · live · background · “Nivolumab Injection [Opdivo]” · registered Dec 2021
  • NCT03684811 · Novo Nordisk A/S · Phase 2 · background · “Nivolumab” · registered Sep 2018
Bristol-Myers Squibb76% of its industry studiesUS: Bristol-Myers Squibb (FDA 2014)EU: Bristol-Myers Squibb (EMA 2015)22 studies
durvalumabRecent, repeated
Evidence
  • NCT06282575 · Jazz Pharmaceuticals · Phase 3 · live · background · “Durvalumab” · registered Feb 2024
  • NCT05712356 · Lisata Therapeutics, Inc. · Phase 2 · background · “Durvalumab” · registered Jan 2023
AstraZeneca84% of its industry studiesUS: AstraZeneca (FDA 2017)EU: AstraZeneca (EMA 2018)22 studies
IpilimumabRecent, repeated
Evidence
  • NCT05921760 · Servier Bio-Innovation LLC · Phase 2 · background · “Ipilimumab” · registered Apr 2023
  • NCT05220722 · TriSalus Life Sciences, Inc. · Phase 2 · background · “Ipilimumab” · registered Jan 2022
Bristol-Myers Squibb91% of its industry studiesUS: Bristol-Myers Squibb (FDA 2011)EU: Bristol-Myers Squibb (EMA 2011)22 studies

17 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
tinengotinib☆ Track2 live phase-3 studies: NCT05948475, NCT07328919TransThera Sciences (Nanjing), Inc.

The 1 in phase 3 with the nearest primary completion, of 24 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (5)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Dec 2026 est.tinengotinib · TransThera Sciences (Nanjing), Inc. · Phase 3 main aimNCT05948475 Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma — primary endpoint: Part A: Incidence, duration, and severity of adverse events (AEs) · 200 enrolled
  • Mar 2027 est.FGFR2/3 Inhibitor CGT4859 · Cogent Biosciences, Inc. · Phase 2 main aimNCT06777316 A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors — primary endpoint: Phase 1: Determine the maximum tolerated dose (MTD) and RP2D of CGT4859 - AEs · 110 enrolled
  • 14 Mar 2027 est.EB-HC01 dual-target CARNK cells · Beijing Biotech · Phase 2 main aimstudied with fludarabinestudied with CyclophosphamideNCT07641036 Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer — primary endpoint: Dose-Limiting Toxicities · 30 enrolled

2 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Cholangiocarcinoma studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Immune checkpoint inhibitors 49 open · Tyrosine kinase inhibitors (TKIs) 40 open · Antimetabolites 18 open · Antimitotic agents 2 open · Angiogenesis inhibitors 1 open

Coming up

80studies finish main data collection within a year7 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 211 Cholangiocarcinoma studies recruiting now, 141 (67%) set no upper age limit and 49 (23%) stop at 75 or younger. 10 (5%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 14 (7%) take healthy volunteers.

Recruiting studies that take each age, of 211
AgeWomenMen
108 (4%)8 (4%)
18200 (95%)200 (95%)
30209 (99%)209 (99%)
40211 (100%)211 (100%)
50211 (100%)211 (100%)
65211 (100%)211 (100%)
75201 (95%)201 (95%)
85154 (73%)154 (73%)

Across all 825 studies, recruiting or not: 17% stop at 75 or younger and 1% at 65; 5% take children; 0% are for women only and 0% for men only; 4% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Cholangiocarcinoma studies take

Of 173 phase 2 interventional studies under Cholangiocarcinoma, half reached primary completion within 46 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 146 mo30–63 · 67 studies41 mo28–60 · 44 studies—
Phase 1/268 mo41–77 · 40 studies——
Phase 246 mo29–65 · 173 studies—46 mo30–65 · 147 studies
Interventional, no phase43 mo28–… · 67 studies—43 mo28–… · 66 studies
Observational60 mo33–… · 70 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 825. Browse all 825 → or search them.